We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 11-20 of 1,150

Sanofi’s Canadian patent on Plavix valid and infringed by Apotex
  • McCarthy Tétrault LLP
  • Canada
  • July 30 2013

On July 24, 2013 the Federal Court of Appeal released its decision reversing the trial court's ruling that Sanofi's patent covering Plavix is


Court grants judicial review of minister of health’s decision
  • Borden Ladner Gervais LLP
  • Canada
  • January 16 2014

Apotex brought this application for judicial review of a decision of the Therapeutic Products Directorate (TPD) refusing to review Apotex’


Pharma in brief - Apotex Inc. and Apotex Pharmachem Inc. are ordered to disgorge profits in excess of $61 million
  • Norton Rose Fulbright Canada LLP
  • Canada
  • July 10 2015

Apotex Inc. (Apotex) and Apotex Pharmachem Inc. (Pharmachem) have been ordered by the Federal Court to pay to Adir and Servier Canada


Astrazeneca Canada Inc. v. Apotex Inc., 2015 FC 671
  • Borden Ladner Gervais LLP
  • Canada
  • July 7 2015

The parties moved under Rule 397 to modify the terms of the judgment in the proceeding, previously reported as 2015 FC 322 and summarized in our


PM(NOC) proceedings: Federal Court of Appeal affirms stringent product specificity requirements for listing patents in Canada
  • McCarthy Tétrault LLP
  • Canada
  • May 6 2015

The Federal Court of Appeal has affirmed the stringent product specificity requirements for listing a patent against a drug for purposes of the


Federal Court rejects generic’s non-infringing alternative defence and awards compound interest for patent infringement damages
  • Norton Rose Fulbright Canada LLP
  • Canada
  • February 2 2015

On January 23, 2015, the Federal Court released its public reasons for Judgment granting Eli Lilly and Company and Eli Lilly Canada, Inc


Canada patented medicines: Federal Court of Appeal confirms mootness of innovator appeals after generic marketing authorization is granted
  • McCarthy Tétrault LLP
  • Canada
  • February 17 2015

"Asking a court to prohibit a notice of compliance after it has issued is like asking someone to close the barn door after the horses have escaped."


After reconsideration, the Viagra patent is not void
  • Fasken Martineau DuMoulin LLP
  • Canada
  • June 11 2013

Close to seven months after rendering its decision in Teva Canada Ltd v Pfizer Canada Inc., 2012 SCC 60, the Supreme Court of Canada varied its


First Canadian antibody decision of Federal Court significant for what it does not say
  • SIM. IP Practice
  • Canada
  • March 21 2014

It has been 15 years since the last brand v brand challenge of a biologic patent in Canada. In 2000, Amgen’s recombinant EPO patent (for EPREX, which


Canada-EU free trade deal: intellectual property issues for the pharmaceutical industry
  • Dentons
  • Canada, European Union
  • October 24 2013

Canada and the European Union (the "EU") have signed a tentative deal to open markets and drop nearly all import taxes on everything from food to